Cytokinetics Inc logo

Cytokinetics Inc(CYTK)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$56.13
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CYTK

11/13/2026: CYTK (2-star) is currently NOT-A-BUY. Pass it for now.

Cytokinetics Inc is a biopharmaceutical company specializing in novel muscle activators designed to treat debilitating cardiovascular and neuromuscular diseases. The company's primary investment appeal centers on the commercialization and global rollout of its flagship late-stage asset, aficamten, for hypertrophic cardiomyopathy. Key strengths include specialized scientific expertise and a robust intellectual property portfolio, though the company faces intense competition from established pharmaceutical rivals and execution risks inherent to scaling commercial operations. It represents a growth-oriented investment profile suited for investors comfortable with clinical and commercialization volatility. Key developments to monitor include prescription adoption rates, international regulatory updates, and ongoing pipeline expansion milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high potential top-line expansion driven by the commercial rollout of novel late-stage drug candidates.
Momentum investorStrong fit while signal remains positiveStock price behavior is heavily influenced by clinical catalysts, regulatory decisions, and short-term market sentiment shifts.
Value investorWeak fitThe lack of consistent earnings and traditional valuation metrics makes it unsuitable for classic value investing strategies.
Dividend investorWeak fitCytokinetics does not pay dividends, focusing instead on reinvesting capital into clinical research and commercial growth.
Low-risk investorWeak fitHigh clinical trial risks, regulatory binary events, and price volatility expose investors to significant downside potential.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotechnology stocks frequently experience sharp price swings around clinical data readouts and regulatory updates.
Valuation riskMedium / highValuations rely heavily on long-term cash flow projections and commercial success assumptions for pipeline assets.
Competition risk (Bristol Myers Squibb and major pharma)HighWell-capitalized competitors can introduce rival treatments that threaten market adoption rates.
Business qualityMediumThe company demonstrates strong scientific innovation capabilities, though commercial execution is still scaling.
Dividend incomeLow / noneNo dividend is paid, meaning total returns depend entirely on capital appreciation.
Execution riskHighSuccessful commercialization, market access, and physician adoption of aficamten are critical to financial viability.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.82B USD
Price to earnings Ratio -
1Y Target Price 109.42
Price to earnings Ratio -
1Y Target Price 109.42
Volume (30-day avg) 2.0M shares
Beta 0.47
52 Weeks Range 53.55 - 88.31
Updated Date 11/15/2026
52 Weeks Range 53.55 - 88.31
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -6.02

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 51.11%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CYTK receives a 3-star rating, supported by strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CYTK has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+376.6%) is partially offset by negative earnings growth (-33.2%), weak cash generation (FCF margin -607.5%), weak profitability (net margin -891.6%).

Financial Health Rating

★★★★★
CYTK's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 50.2%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CYTK's strongest growth driver at +376.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-33.2%, negative) and free-cash-flow growth (-33.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 128.0% and approximately 99.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.20% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 14.43%
T. Rowe Price Investment Management,Inc. 13.45%
Wellington Management Company LLP 4.98%
Vanguard Portfolio Management, LLC 4.82%
State Street Corp 4.66%

Unit Economics (Per $1K Revenue)

★★★★★
CYTK generates approximately $885 of gross profit, $-6,954 of operating income, and $-6,075 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CYTK has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Cardiovascular Therapeutics CommercializationGlobal sales of specialized heart disease treatments such as aficamten following regulatory approvals.This is the primary future growth engine where prescription sales translate directly into corporate revenue.
Strategic Collaborations and LicensingUpfront payments, development milestones, and royalties from international pharmaceutical partnerships.Provides non-dilutive capital funding and expands global market reach via regional partners.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 117.65
Enterprise Value 7.95B
Price to Sales(TTM) 69.02
Enterprise Value 7.95B
Price to Sales(TTM) 69.02
Enterprise Value to Revenue 70.2
Enterprise Value to EBITDA -15.82
Shares Outstanding 139.30M
Shares Floating 138.78M
Shares Outstanding 139.30M
Shares Floating 138.78M
Percent Insiders 1.2
Percent Institutions 127.96

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.